Thomas Först

13.4k total citations · 2 hit papers
228 papers, 7.5k citations indexed

About

Thomas Först is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Surgery. According to data from OpenAlex, Thomas Först has authored 228 papers receiving a total of 7.5k indexed citations (citations by other indexed papers that have themselves been cited), including 156 papers in Endocrinology, Diabetes and Metabolism, 61 papers in Molecular Biology and 54 papers in Surgery. Recurrent topics in Thomas Först's work include Diabetes Treatment and Management (92 papers), Diabetes Management and Research (84 papers) and Metabolism, Diabetes, and Cancer (50 papers). Thomas Först is often cited by papers focused on Diabetes Treatment and Management (92 papers), Diabetes Management and Research (84 papers) and Metabolism, Diabetes, and Cancer (50 papers). Thomas Först collaborates with scholars based in Germany, United States and Austria. Thomas Först's co-authors include Andreas Pfützner, T. Kunt, G Lübben, C Hohberg, M Hanefeld, Peter Herbert Kann, Matthias Langenfeld, Thomas R. Konrad, Christoph Kapitza and Matthias M. Weber and has published in prestigious journals such as The Lancet, Circulation and Journal of Clinical Investigation.

In The Last Decade

Thomas Först

216 papers receiving 7.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study

2012 460 citations Thomas Först et al. profile →
Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial

2014 391 citations Thomas Först et al. profile →

Peers

Countries citing papers authored by Thomas Först

Since Specialization

Citations

This map shows the geographic impact of Thomas Först's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Först with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Först more than expected).

Fields of papers citing papers by Thomas Först

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Först. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Först. The network helps show where Thomas Först may publish in the future.

Co-authorship network of co-authors of Thomas Först

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Först. A scholar is included among the top collaborators of Thomas Först based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Först. Thomas Först is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Tirzepatide reduces HbA1c and body weight significantly more than placebo or semaglutide irrespective of baseline beta-cell function: post-hoc analysis from SURPASS-1 and SURPASS-2 2024 ·Diabetologie und Stoffwechsel ·(unknown), Christophe De Block, Juan P. Frías, Clare J. Lee, Katelyn Brown, Hui Wang, Melissa K. Thomas, Thomas Först	1
2	Performance of a Novel Continuous Glucose Monitoring Device in People With Diabetes 2024 ·Journal of Diabetes Science and Technology ·Julia K. Mader, Delia Waldenmaier, (unknown), (unknown), (unknown), Gerhard Vogt, (unknown), Manuel Eichenlaub, Thomas Först, Guido Freckmann	6
3	The role of incretin receptor agonists in the treatment of obesity 2024 ·Diabetes Obesity and Metabolism ·Thomas Först, Christophe De Block, Stefano Del Prato, (unknown), Juan P. Frías, Anne Lautenbach, (unknown), (unknown), Chantal Mathieu, Timo D. Müller, Oliver Schnell	10
4	Effect of changes in metabolic enzymes and transporters on drug metabolism in the context of liver disease: Impact on pharmacokinetics and drug–drug interactions 2023 ·British Journal of Clinical Pharmacology ·(unknown), Andreas Geier, Thomas Först, Uta Merle, David Alpers, Martin W. Lunnon	16
5	The Role of Ultra-Rapid-Acting Insulin Analogs in Diabetes: An Expert Consensus 2023 ·Journal of Diabetes Science and Technology ·Francesco Giorgino, Tadej Battelino, Richard M. Bergenstal, Thomas Först, Jennifer B. Green, Chantal Mathieu, Helena W. Rodbard, Oliver Schnell, Emma G. Wilmot	5
6	Evaluation of Non-Alcoholic Fatty Liver Disease (NAFLD) in Obese Adult Volunteers According to Increasing Insulin Resistance and Loss of Glucose Control 2022 ·Thomas Först	2
7	A practical approach to the clinical challenges in initiation of basal insulin therapy in people with type 2 diabetes 2020 ·Diabetes/Metabolism Research and Reviews ·Thomas Först, Pratik Choudhary, Doron Schneider, Bruno Linetzky, Paolo Pozzilli	18
8	Anti-diabetic treatment regulates pro-fibrotic TGF-β serum levels in type 2 diabetics 2013 ·Diabetology & Metabolic Syndrome ·Stefan Pscherer, Thomas Freude, Thomas Först, Andreas K. Nüssler, Karl F. Braun, Sabrina Ehnert	20
9	Addition of liraglutide in patients with Type 2 diabetes well controlled on metformin monotherapy improves several markers of vascular function 2012 ·Diabetic Medicine ·Thomas Först, Georg Michelson, Frank Ratter, Matthias M. Weber, (unknown), Michael Mitry, (unknown), A Pfützner	63
10	Accuracy Evaluation of Five Blood Glucose Monitoring Systems Obtained from the Pharmacy: A European Multicenter Study with 453 Subjects 2011 ·Diabetes Technology & Therapeutics ·(unknown), (unknown), Thomas Behnke, Volkmar H.R. Schmid, (unknown), Thomas Först, Andreas Pfützner	71
11	PIOfix-Study: Effects of Pioglitazone/Metformin Fixed Combination in Comparison with a Combination of Metformin with Glimepiride on Diabetic Dyslipidemia 2011 ·Diabetes Technology & Therapeutics ·Andreas Pfützner, Thomas Schöndorf, Diethelm Tschöpe, Ralf Lobmann, Jürgen Merke, Jürgen Müller, Ute Lehmann, W Fuchs, Thomas Först	15
12	Competact, a Fixed Combination of Pioglitazone and Metformin, Improves Metabolic Markers in Type 2 Diabetes Patients with Insufficient Glycemic Control by Metformin Alone—Results from a Post-Marketing Surveillance Trial Under Daily Routine Conditions 2009 ·Diabetes Technology & Therapeutics ·Thomas Schöndorf, Efstrathios Karagiannis, (unknown), Thomas Först, Andreas Pfützner	5
13	The influence of advanced glycation endproducts (AGE) on the expression of human endothelial adhesion molecules 2009 ·Experimental and Clinical Endocrinology & Diabetes ·T. Kunt, Thomas Först, Oliver Harzer, (unknown), Andreas Pfützner, M Löbig, (unknown), E Stofft, M. Engelbach, J. Beyer	16
14	New aspects on biological activity of C-peptide in IDDM patients 2009 ·Experimental and Clinical Endocrinology & Diabetes ·Thomas Först, T. Kunt, Andreas Pfützner, J. Beyer, J. Wahren	8
15	Prädiktive genetische Untersuchungen: Individualisierung von Diagnostik und Therapie bei Familien mit multipler endokriner Neoplasie Typ II 2008 ·DMW - Deutsche Medizinische Wochenschrift ·M. Engelbach, T. Kunt, (unknown), Burkhard Manfras, Thomas Hankeln, Thomas Först, Andreas Pfützner, (unknown), (unknown), (unknown), J. Beyer	1
16	Anti-Inflammatory Effects of Pioglitazone and/or Simvastatin in High Cardiovascular Risk Patients With Elevated High Sensitivity C-Reactive Protein 2007 ·Journal of the American College of Cardiology ·M Hanefeld, Nikolaus Marx, Andreas Pfützner, (unknown), G Lübben, Efstrathios Karagiannis, (unknown), Thomas Först	141
17	Impact of insulin on microvascular blood flow and endothelial cell function in the postprandial state in patients with Type 1 diabetes 2005 ·Journal of Diabetes and its Complications ·Thomas Först, S Först, (unknown), (unknown), (unknown), Christof Kazda, Andreas Pfützner	18
18	Improvement of Cardiovascular Risk Markers by Pioglitazone Is Independent From Glycemic Control 2005 ·Journal of the American College of Cardiology ·Andreas Pfützner, Nikolaus Marx, G Lübben, Matthias Langenfeld, Daniel Walcher, Thomas R. Konrad, Thomas Först	233
19	Bone Mineral Density and Bone Metabolism in Diabetes Mellitus 1997 ·Hormone and Metabolic Research ·(unknown), Peter Herbert Kann, Thomas Först, J. Andreas, A Pfützner, J. Beyer	112
20	Evaluation of neuropathic involvement by fibre type in patients with either insulin-dependent or non-insulin dependent diabetes with and without neurotrophic foot ulceration 1995 ·Thomas Först, Andreas Pfützner, (unknown), Hendrik Lehnert, J. Beyer	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact